LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Elenco Azioni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Chiusa

4.18 11.47

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.75

Massimo

4.21

Metriche Chiave
By Trading Economics
Entrata	466K -27M
Vendite	2M 15M
Margine di Profitto	-178.834
Dipendenti	141
EBITDA	-2M -29M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+278.09% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	5.9M 234M
Apertura precedente	-7.29
Chiusura precedente	4.18

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

3.17 / 3.4644 Supporto e resistenza

Voyager Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 23:41 UTC

Utili

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mag 2026, 21:40 UTC

Utili

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mag 2026, 23:12 UTC

Utili

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mag 2026, 23:11 UTC

Utili

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:07 UTC

Utili

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mag 2026, 23:05 UTC

Utili

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mag 2026, 23:04 UTC

Utili

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mag 2026, 22:25 UTC

Discorsi di Mercato

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mag 2026, 22:05 UTC

Discorsi di Mercato

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mag 2026, 21:58 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:47 UTC

Discorsi di Mercato

Utili

Costco Posts 13% Sales Growth in April -- Market Talk

6 mag 2026, 21:46 UTC

Utili

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mag 2026, 21:40 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:35 UTC

Discorsi di Mercato

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mag 2026, 21:32 UTC

Azioni calde

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mag 2026, 21:29 UTC

Utili

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Voyager Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

278.09% in crescita

Previsioni per 12 mesi

Media 14.67 USD 278.09%

Alto 25 USD

Basso 8 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Voyager Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Voyager Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

3.17 / 3.4644Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.